In fact, pioglitazone, an antidiabetic drug which acts also by activating AMPK[76], has been proven to reverse pathological conditions in an animal model of the disease[77] and it is in clinical trial for Alzheimer’s disease (http://www.clincaltrial.gov). The gene discussed is PRKAA2; the disease is early-onset autosomal dominant Alzheimer disease.